After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma ...

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting ...

Kennedy, a long-time opponent of vaccines, stated that the MMR vaccine is “the most effective way” to combat the measles ...

Health-focused nonprofits like the Drug Information Association (DIA) serve as crucial bridge-builders in the healthcare ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...

With the recently announced layoffs of 3,500 FDA staffers and exits of branch directors Patrizia Cavazzoni and Peter Marks, ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...